podcast
What relation does JD Vance have with Vivek Ramaswamy?
Do pharma companies have a moral responsibility to patients? And what does $300 champagne taste like?
We cover all that and more in this week's episode of "The Readout LOUD," STAT's biotech podcast. Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election.
Listen here.
glp-1 drugs
Novo, Lilly shares sink due to concerns over competition
Eli Lilly and Novo Nordisk saw their shares sink further this week thanks to looming competition in the anti-obesity market. Lilly's shares dropped 10% over just two days, and Novo's are down about 8% in the same time period — cutting tens of billions of dollars in market share, the Wall Street Journal points out.
This follows Wednesday's news from Roche that its experimental pill prompted pronounced weight loss in early studies. Although there's a ways to go with the Roche drug, this suggests that the company — or others — could ultimately gobble up market share should it win approval.
No comments